Ser262
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.0.1
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser262  -  ARAF (human)

Site Information
RGsPsPAsVssGRKs   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 3306309

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 ) , mutation of modification site ( 2 )
Disease tissue studied:
HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 )
Relevant cell line - cell type - tissue:
breast ( 1 ) , COS (fibroblast) ( 2 )

Upstream Regulation
Treatments:
EGF ( 2 )

Downstream Regulation
Effects of modification on ARAF:
enzymatic activity, induced ( 2 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Baljuls A, et al. (2008) Positive regulation of A-RAF by phosphorylation of isoform-specific hinge segment and identification of novel phosphorylation sites. J Biol Chem 283, 27239-54
18662992   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2019 Cell Signaling Technology, Inc.